Neurologic complications in herpes simplex encephalitis: clinical, immunological and genetic studies
Brain · 03.10.2023 · 146 (10) · 4306-4319
DOI: 10.1093/brain/awad238 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain, online erschienen am 15.07.2023. Verfasst von Thaís Armangué und 29 weiteren Autor:innen. Beteiligte Einrichtung: Neuroimmunology Program, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, 08036 Barcelo…. Hauptthemen laut MEDLINE: Encephalitis, Herpes Simplex, Nervous System Diseases, Interferon Type I. Die Arbeit wurde bisher 94-mal zitiert (Crossref) und nennt 43 Literaturangaben.
Abstract (Originalsprache)
Patients with herpes simplex virus (HSV) encephalitis (HSE) often develop neuronal autoantibody-associated encephalitis (AE) post-infection. Risk factors of AE are unknown. We tested the hypotheses that predisposition for AE post-HSE may be involved, including genetic variants at specific loci, human leucocyte (HLA) haplotypes, or the blood innate immune response against HSV, including type I interferon (IFN) immunity. Patients of all ages with HSE diagnosed between 1 January 2014 and 31 December 2021 were included in one of two cohorts depending on whether the recruitment was at HSE onset (Spanish Cohort A) or by the time of new neurological manifestations (international Cohort B). Patients were assessed for the type of neurological syndromes; HLA haplotypes; blood type I-IFN signature [RNA quantification of 6 or 28 IFN-response genes (IRG)] and toll-like receptor (TLR3)-type I IFN-related gene mutations. Overall, 190 patients (52% male) were recruited, 93 in Cohort A and 97 in Cohort B. Thirty-nine (42%) patients from Cohort A developed neuronal autoantibodies, and 21 (54%) of them developed AE. Three syndromes (choreoathetosis, anti-NMDAR-like encephalitis and behavioural-psychiatric) showed a high (≥95% cases) association with neuronal autoantibodies. Patients who developed AE post-HSE were less likely to carry the allele HLA-A*02 (4/21, 19%) than those who did not develop AE (42/65, 65%, P = 0.0003) or the Spanish general population (2005/4335, 46%, P = 0.0145). Blood IFN signatures using 6 or 28 IRG were positive in 19/21 (91%) and 18/21 (86%) patients at HSE onset, and rapidly decreased during follow-up. At Day 21 after HSE onset, patients who later developed AE had higher median IFN signature compared with those who did not develop AE [median Zs-6-IRG 1.4 (0.6; 2.0) versus 0.2 (−0.4; 0.8), P = 0.03]. However, a very high median Zs-6-IRG (>4) or persistently increased IFN signature associated with uncontrolled viral infection. Whole exome sequencing showed that the percentage of TLR3-IFN-related mutations in patients who developed AE was not different from those who did not develop AE [3/37 (8%) versus 2/57 (4%), P = 0.379]. Multivariate logistic regression showed that a moderate increase of the blood IFN signature at Day 21 (median Zs-6-IRG >1.5 but <4) was the most important predictor of AE post-HSE [odds ratio 34.8, interquartile ratio (1.7–691.9)]. Altogether, these findings show that most AE post-HSE manifest with three distinct syndromes, and HLA-A*02, but not TLR3-IFN-related mutations, confer protection from developing AE. In addition to neuronal autoantibodies, the blood IFN signature in the context of HSE may be potentially useful for the diagnosis and monitoring of HSE complications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neuroimmunology Program, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, 08036 Barcelona, Spain.
- Pediatric Neuroimmunology Unit, Neurology Department, Sant Joan de Déu Children's Hospital, University of Barcelona, 08950 Esplugues de Llobregat, Barcelona, Spain.
- Pediatric Neurology Unit, Parc Taulí Hospital Universitari, 08208 Sabadell, Barcelona, Spain.
- Neuroimmunology Unit, Service of Neurology, Hospital Clínic, Universitat de Barcelona, 08036 Barcelona, Spain.
- Center for Sleep Science and Medicine, Stanford University, Stanford, CA 94304, USA.
- Immunology Department, Hospital Clínic, Centre de Diagnòstic Biomèdic, 08036 Barcelona, Spain.
ORCID-Profile: Thaís Armangué, Jesus Planagumà, Emmanuel Mignot
Zitieren
APA
Armangué, T., Olivé-Cirera, G., Martínez-Hernandez, E., Rodes, M., Peris-Sempere, V., Guasp, M., Ruiz, R., Palou, E., González, A., Marcos, M. Á., Erro, M. E., Bataller, L., Corral-Corral, Í., Planagumà, J., Caballero, E., Vlagea, A., Chen, J., Bastard, P., Materna, M., …, & Dalmau, J. (2023). Neurologic complications in herpes simplex encephalitis: clinical, immunological and genetic studies. Brain, 146(10), 4306-4319. https://doi.org/10.1093/brain/awad238
Vancouver
Armangué T, Olivé-Cirera G, Martínez-Hernandez E, Rodes M, Peris-Sempere V, Guasp M, et al. Neurologic complications in herpes simplex encephalitis: clinical, immunological and genetic studies. Brain. 2023;146(10):4306-4319. doi:10.1093/brain/awad238
BibTeX
@article{Armangu2023,
author = {Armangué, Thaís and Olivé-Cirera, Gemma and Martínez-Hernandez, Eugenia and Rodes, Maria and Peris-Sempere, Vicente and Guasp, Mar and Ruiz, Raquel and Palou, Eduard and González, Azucena and Marcos, Ma Ángeles and Erro, María Elena and Bataller, Luis and Corral-Corral, Íñigo and Planagumà, Jesus and Caballero, Eva and Vlagea, Alexandru and Chen, Jie and Bastard, Paul and Materna, Marie and Marchal, Astrid and Abel, Laurent and Cobat, Aurélie and Alsina, Laia and Fortuny, Clàudia and Saiz, Albert and Mignot, Emmanuel and Vanderver, Adeline and Casanova, Jean-Laurent and Zhang, Shen-Ying and Dalmau, Josep},
title = {Neurologic complications in herpes simplex encephalitis: clinical, immunological and genetic studies},
journal = {Brain},
year = {2023},
volume = {146},
number = {10},
pages = {4306--4319},
doi = {10.1093/brain/awad238}
}
EUVIMED